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Abstract
Motivation: Class C G protein-coupled receptors (GPCRs) regulate important physiological func-
tions and allosteric modulators binding to the transmembrane domain constitute an attractive
and, due to a lack of structural insight, a virtually unexplored potential for therapeutics and the
food industry. Combining pharmacological site-directed mutagenesis data with the recent class
C GPCR experimental structures will provide a foundation for rational design of new
therapeutics.
Results: We uncover one common site for both positive and negative modulators with different
amino acid layouts that can be utilized to obtain selectivity. Additionally, we show a large potential
for structure-based modulator design, especially for four orphan receptors with high similarity to
the crystal structures.
Availability and Implementation: All collated mutagenesis data is available in the GPCRdb muta-
tion browser at http://gpcrdb.org/mutations/ and can be analyzed online or downloaded in excel
format.
Contact: david.gloriam@sund.ku.dk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Class C of G protein-coupled receptors (GPCRs) consists of five re-
ceptor families (Alexander et al., 2015): eight metabotropic glutam-
ate receptors (mGlu1-8) sub-divided into three groups (Conn and
Pin, 1997), two GABA receptors (GABAB1-2) (Pinard et al., 2010),
three taste 1 receptors, (TAS1R1-3) (Treesukosol et al., 2011), the
calcium-sensing (CaS) and GPRC6 receptors, and seven orphan re-
ceptors, GPR156, GPR158, GPR179 and GPRC5A-D. The mGlu
and GABAB receptors regulate neuronal transmission throughout
the central nervous system and have been implicated in many high-
interest diseases as e.g. Parkinson’s. In addition to the well-known
functions of the CaS receptor it has been implicated in e.g.
Alzheimer’s disease. The taste 1 receptors are responsible for umami
and sweet taste and a broad expression pattern may indicate other
physiological functions. Physiological function and therapeutic
utilization of orphan receptors are unknown and are being debated
for the GPRC6 receptor (Clemmensen et al., 2014) (Supplementary
Table S1).
Allosteric modulators (AMs) that bind in the transmembrane do-
main (TMD) comprised of seven helices (TM1-7) have now been dis-
covered for all non-orphan class C GPCR families with potential
therapeutic advantages by enhancing or attenuating the normal receptor
response without interfering with the N-terminal domain orthosteric site
(Lu et al., 2014). Furthermore, AMs potentially offer better receptor
subtype selectivity and biased signalling, which in concert can lead to
fewer undesirable side-effects (Nickols and Conn, 2014). This allosteric
site in class C GPCRs constitute targets for therapeutics as well as for
the food industry (Supplementary Table S1), exemplified by the mar-
keted drug cinacalcet, a CaS receptor positive AM (PAM) (Nemeth and
Shoback, 2013) and a Parkinson’s disease clinical trial with dipraglurant,
a mGlu5 negative AM (NAM) by Addex Pharma (Tison et al., 2016).
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The binding sites of class C GPCR AMs have been extensively
studied using site-directed mutagenesis and receptor structure mod-
els (Gregory and Conn, 2015), but the lack of class C structures lim-
ited the resolutions of these analyses, hampering the translation of
mutagenesis effects and models into pharmacological mechanisms
and prospective rational structure-based drug design. Similarly to
previously published work on class A GPCRs (Hulme, 2013), the re-
cent mGlu structures (Christopher et al., 2015; Dore et al., 2014;
Wu et al., 2014) has herein opened up for the first consistent com-
parison of all published class C GPCR mutants in the TMD. We pin-
point the location of the allosteric sites, and integrate mutant and
structural data towards rational design of new modulators.
2 Methods
2.1 Annotation of literature single-point mutations
We manually annotated 1670 data points from 35 publications with
single-point mutations tested on 70 AMs and made them available
online in the GPCR database, GPCRdb (Isberg et al., 2016). These
mutants cover 99 TMD helix and several extracellular loop pos-
itions within the CaS, GABAB2 (not shown, as all reported single-
point mutations had low effect on PAM function), GPRC6, mGlu1,
mGlu2, mGlu4, mGlu5 and TAS1R3 receptors. Residue positions,
numbered according to the GPCRdb generic scheme (Isberg et al.,
2015), were considered as potential ligand binding if they have
>5-fold effect on AM binding or function (Figs 2A, 3A).
2.2 Sequence alignment, similarities and
phylogenetic trees
The sequence alignments and similarities (Supplementary Figs S1, S2
and Table S2) of the 22 human class C GPCRs was calculated and
downloaded from GPCRdb (Isberg et al., 2016) The phylogenetic
trees (Fig. 1) were calculated with the PHYLIP package, v. 3.695
(Felsenstein, 1989), based on the above alignments using the protd-
ist and neighbor programs with UPGMA clustering and rendered by
an in-house javascript using D3.js.
2.3 Crystal structure binding site residues
The mGlu5 (PDB codes, 4OO9, 5CGC and 5CGD) and mGlu1 (PDB
code 4OR2) crystal structures were downloaded from the Protein
Data Bank (www.rcsb.org) and the PyMOL Molecular Graphics
System, version 1.8, Schro¨dinger, LLC was used to prepare Figures 2B
and 3B and determine the residue positions in the allosteric binding
site by selecting residues with Ca or side chain atoms5 A˚ of any
co-crystallized NAM atom.
3 Results
3.1 The class C GPCR families group consistently for the
transmembrane domain and allosteric modulator site
Class C GPCRs are classified into families by endogenous ligand
(Southan et al., 2016) (Supplementary Table S1), which bind in the
extracellular N-terminal domain, while the reported AMs bind in
the distinct TMD. Thus, it is crucial to establish if these receptor
families are valid also for the analysis of AMs. We constructed
phylogenetic trees based on the TMD and common allosteric site
(below) sequence alignments (Figs 1, S1 and S2). In both trees, the
receptor families with a known physiological ligand display a coher-
ent grouping of all members. In addition, the orphan receptors are
divided into two groups with the exception of GPR156, which, in
agreement with earlier reports (Calver et al., 2003), groups with the
GABAB receptors. This confirms that the established receptor fami-
lies can indeed serve as a basis to map allosteric data, and as target
profiles for ligand selectivity and inference.
3.2 Class C GPCR negative and positive allosteric
modulators bind in one common transmembrane
domain site
An overall TMD allosteric site in the class C GPCRs can be
delineated from the mGlu structures and the collated mutagenesis
data. In total, 28 residue positions line the TMD pocket and to-
gether represent the overall potential AM contacts (Fig. 2). Notably,
these exhibit strong experimental evidence: 26 positions are in close
vicinity (5 A˚) of the co-crystallized modulators, and 23 have dem-
onstrated effect (>5-fold) upon mutagenesis (Fig. 2A). Nine AM
binding hotspots, 2x56, 3x32, 3x36, 5x43, 6x50, 6x53, 6x57, 7x37
and 7x40, span three receptor families. The latter six positions are
supported by mutant effect on 10 or more different ligands while
mutations in the central part of the binding site, i.e. positions 6x50
and 6x53 show effect on 37 and 24 different ligands, respectively, in
six different receptors (Supplementary Table S3). Furthermore, 68%
of the positions re-occur in at least two families demonstrating a
Fig. 2. Common allosteric binding site. (A) 28 binding site positions from crys-
tal structures and mutagenesis data. (B) Mapping onto the mGlu5 structure
(Ca-spheres) including the NAM, mavoglurant. (C) Venn diagram (Color ver-
sion of this figure is available at Bioinformatics online.)
Fig. 1. Phylogenetic trees of class C GPCRs based on (A) the TMD and (B) the
common allosteric site. Both trees group according to the families based on
endogenous ligands binding in the N-terminus (Color version of this figure is
available at Bioinformatics online.)
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substantial overlap of the class C GPCR modulator sites. Structural
mapping pinpoints an allosteric site that, as for most class A GPCR
ligands, is located mainly between TM3 and TM5-7, with additional
contacts to TM2 and the second extracellular loop (Fig. 2B).
Notably, 87% of the mutated binding site positions are involved in
both NAM and PAM binding and/or function (Fig. 2A, C) and the
concordant structural and mutagenesis data strongly suggests the ex-
istence of a common allosteric binding site for both types of modula-
tors with substantial overlap across the class C receptor families.
3.3 The second extracellular loop is involved in binding
The second extracellular loop of GPCRs typically forms a disulphide
bridge to the top of TM3, placing the loop as a lid on the TMD pocket
(Wu et al., 2014), often in direct ligand contact (de Graaf et al., 2008). It
is constituted by a pair of cysteine residues (3x29 and 45x50) only absent
in GPR156, GPRC5A and GPRC5D (Supplementary Fig. S1); indicating
that the second extracellular loop is close to the AM site in nearly all class
C GPCRs. Mutagenesis data reports effect on the position before (45x49)
and four consecutive positions after (45x51-54) the conserved cysteine
(Figs 2A, B, 3A, B and online in GPCRdb), while the mGlu structures
only show one position (45x52) in direct contact with a NAM and an
additional position (45x49) with the side chain pointing towards the AM
site. This is expected as the many class A GPCR structures (Wheatley
et al., 2012) show the flexibility and varying length of the second extra-
cellular loop to bring alternative positions into vicinity of the AM site.
3.4 The mGlu5 receptor features a unique site extension
The mGlu5 receptor structures contain a unique site extension located
between TM2, 3 and 7 (Fig. 3A, B) that can be exploited to achieve se-
lective NAM binding (Harpsøe et al., 2015). Its uniqueness is sup-
ported by mutagenesis of the site extension position 7x41 in four
different receptors with a selective effect in mGlu5 (Supplementary
Table S3 and online in GPCRdb), and a gateway position 3x40 hold-
ing a mGlu5-specific Pro, which significantly decreases or abolishes
AM binding or activity when mutated (Gregory et al., 2013; Mølck
et al., 2012). Most other class C GPCRs contain bulkier sidechains in
position 3x40 and in another crucial position, Gly2x49 (Harpsøe
et al., 2015) (Supplementary Fig. S1). In spite of this, a 6.7-fold PAM
affinity decrease by a CaS receptor mutation in position 7x44 (Fig.
3A) in one of two assays (Leach et al., 2016) challenges the unique-
ness of the site extension. However, as a drastic F3x40A mutation in
the site extension gateway position does not support this finding, it is
tempting to consider it as an experimental outlier. In all, the data sug-
gest that the extension of the modulator site in mGlu5 is unique not
only within the mGlu receptors, but within all class C GPCRs.
3.5 A TM1 mutation may reveal a group I mGlu receptor
dimer interface PAM site
In contrast to the clearly overlapping data in the common allosteric
site (Fig. 2) several positions outside the common allosteric site have
shown only PAM or NAM effect (Fig. 3A). However, as the muta-
tional effects can be rationalized by other reasons (see below) they
are not considered as functionally specific sites.
One exception is position 1x46 that face the cell membrane,
where a Phe-to-Ile mutation abolishes the effect of the mGlu1 and
mGlu5 PAM, CPPHA (Chen et al., 2008), while it has no effect on
other PAMs and NAMs (online in GPCRdb). The mGlu1 structure
depicts a dimeric complex implicating TM1 of both protomers (Wu
et al., 2014) and, though the functional dimer interface of mGlu2
has been shown to involve TM4-6 (Xue et al., 2015), it may be func-
tionally important in group I mGlu receptors. The interface in this
inactive state structure does not directly involve Phe1x46, but it may
do so in the active state conformation of the receptor and take part
in forming a specific PAM site explaining the observed mutational
effects for CPPHA. Regardless of TM1 being part of a functional
dimer interface, the fact remains, that among 22 positions only mu-
tation of 1x46 showed effect on CPPHA modulation and it does not
compete with modulators binding in the common allosteric site
(Gregory et al., 2011) showing the presence of at least one add-
itional allosteric site.
3.6 Three TM5 and 6 mutations hamper the interactions
of other adjacent residues
The combination of structures and mutagenesis data also provides
the opportunity to filter out the data points that are not related to a
direct receptor-ligand interaction but rather reflects a secondary ef-
fect. Mutation of 5x48 can affect modulator binding in mGlu5 but
not in mGlu2 and mGlu4 and the effect was only observed for two of
30 tested AMs (Supplementary Table S3). An explanation is pro-
vided from different mGlu5-NAM structure complexes, wherein
Gly5x48 allows for the adjacent Trp6x50 to alternate between the
NAM site (Christopher et al., 2015) and packing between TM5-6
(Dore et al., 2014). Apart from mGlu5, only mGlu1, GABAB1-2,
TAS1R1 and GPR156 have a Gly in 5x48 potentially allowing the
induced fit of modulators through Trp6x50. Furthermore, 6x58 and
6x54 are located outside of the binding site but have exhibited up to
10- and 66-fold effects, respectively (Gregory et al., 2013).
Structural analysis show these residues to have stabilizing inter-
actions to adjacent positions that mediate AM contacts (5x44, 6x53
and 6x57), e.g. in mGlu5 Tyr6x57 display p-p interactions to
Phe6x58 (Dore et al., 2014).
3.7 Glycine mutations perturb TM4 and 7 helical
structure
Relative to other residues, glycines allow for additional backbone
torsional angles and introduce more flexibility (Bywater and
Veryazov, 2015). Mutation of two Gly positions, 4x42 and 7x43,
that face the cell membrane and TM6, respectively, have been
shown to affect modulator binding. Specifically, a Gly-to-Val
Fig. 3. Positions outside the common allosteric binding site. (A) 24 positions
from crystal structures and mutagenesis data. (B) Mapping onto the mGlu5
structure (Ca-spheres; 45x54 is absent in the structure) (C) Venn diagram
(Color version of this figure is available at Bioinformatics online.)
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mutation of position 4x42 yielded>55-fold effect on the mGlu2
PAM, JNJ-41482012 (Farinha et al., 2015), and a Gly-to-Ala/Val
mutation in 7x43 reduced/abolished activation of TAS1R3 by the
allosteric agonist NHDC (Winnig et al., 2007). Importantly, muta-
tion in 4x42 has no effect when the native residue is not a Gly: Val-
to-Ile and Leu-to-Val in mGlu1 and mGlu4, respectively, have no ef-
fect on several AMs (online in GPCRdb). Together, this indicates
that these subtype specific Gly residues are associated with distinct
receptor structures, such as a helical kink or rotation implicating
additional class C GPCRs with a Gly at 4x42 (GPR179) or 7x43
(CaS and GPRC6 receptors) (Supplementary Fig. S1). It would be of
interest to mutate Gly4x42 in the CaS and GPRC6 receptors,
whereas mutations of Gly7x43 can currently not be tested on the or-
phan GPR179 due to lack of ligands.
3.8 Mutated positions with weak and rare effects
The remaining mutated positions in Figure 3, 1x42, 3x41, 4x50,
4x51, 5x37, 7x38 and 7x47, are distant to the common allosteric
site and have relatively subtle effects reported for only one AM on
one receptor (Supplementary Table S3). Of note, the AMs affected
by mutations in these positions are all more pronouncedly affected
by mutation in other positions within the common allosteric site.
Taken together, it is fair to conclude that these mutants probably
give their effect through other processes, such as e.g. binding site
entry/exit or stabilization of an (in)active receptor state, or represent
experimental outliers.
4 Discussion
The available structural templates, which are all NAM-complexes,
map as well to the PAM as the NAM mutagenesis data (Fig. 2). This
is in line with the many class A GPCR-agonist and -antagonist struc-
ture complexes which exhibit moderate differences in the TMD lig-
and binding site (Kruse et al., 2013). This suggests that the mGlu1
and mGlu5 structures could be valid templates also for the design of
PAMs. However, to avoid bias toward NAM activity, it is advisable
to first optimize the structural templates around a high-affinity
PAM, which has previously been successful in GPCR virtual screen-
ing (Vilar et al., 2011). Furthermore, AMs have increasingly been
associated with biased agonism, including CaS (Cook et al., 2015;
Leach et al., 2016) and mGlu5 (Sengmany and Gregory, 2016) re-
ceptors, and it could be expected that several already existing and
future AMs share this phenomenon.
An advantage of allosteric ligands is their ability to achieve
higher receptor target selectivity. As shown in Figure 2, the allosteric
site is largely the same across the class C receptor families, which
could imply less selective binding. However, sequence alignment of
the 28 positions that constitute the common allosteric site shows
that, in spite of many positions displaying more than 60% conserva-
tion of side chain properties (e.g. 86% of the receptors contain an
aromatic residue in position 6x53—Supplementary Fig. S2), there
are a number of family- and subtype-unique residues. Thus, as
shown for the mGlu receptors (Harpsøe et al., 2015), selective
modulators may be achieved by exploiting these as selectivity hot-
spots. This is also supported by the known chemistry, as prototyp-
ical AMs (Supplementary Fig. S3) display highly diverse structures.
Modelling of class C GPCR-AM complexes has become more ac-
cessible with the possibility to utilize the mGlu structures in combin-
ation with our collation of literature mutations, which are available
for visualization and download in GPCRdb. We previously demon-
strated that such data was sufficient to build conclusive models ex-
plaining mGlu NAM selectivity (Harpsøe et al., 2015). Interestingly,
the receptors that displays the closest homology within the allosteric
site (50–64%) are the orphan GPRC5A-D receptors (Supplementary
Table S2). This is encouraging for the prospects of identifying lig-
ands through receptor structure-based virtual screening. Notably,
since the orphan receptors lack the extracellular domain (Kniazeff
et al., 2011), it is plausible that the TMD site constitutes their
orthosteric site in line with the fact that other class C GPCRs can be
activated via the allosteric site, even without the N-terminal domain
(Binet et al., 2004; Goudet et al., 2004). Identification of the en-
dogenous ligands or even the first tool compounds would be very
valuable for the characterization of physiological functions, cellular
localizations and therapeutic potential.
In conclusion, the accumulated mutagenesis data for AMs on
class C GPCRs almost exclusively maps to one common inter-helical
allosteric site for both PAMs and NAMs, which corresponds very
well with the allosteric site in the mGlu crystal structures. The com-
bined mGlu-NAM structure complexes, mutagenesis data, sequence
comparisons and known NAMs/PAMs lays a stronger foundation
for rational design of novel modulators through the construction of
high quality homology models. Specifically, structures, mutagenesis
data and sequence comparisons have been combined in GPCRdb to
create an online tool to design new mutagenesis experiments (Munk
et al., 2016). This design aids researchers by selecting the mutations
with the highest observed involvement in modulator binding, while
avoiding indirect effects through adjacent residues or due to perturb-
ation of the backbone structure. Given the disease relevance of sev-
eral class C GPCRs, it will be intriguing to explore the integration of
data for the identification of potent target- and maybe pathway-
specific novel modulators towards more efficient drugs with less ad-
verse effects.
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